HC Wainwright Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock.

AC Immune Stock Performance

Shares of NASDAQ ACIU opened at $2.30 on Friday. AC Immune has a fifty-two week low of $2.19 and a fifty-two week high of $4.98. The company has a market cap of $227.56 million, a price-to-earnings ratio of -5.00 and a beta of 1.23. The business’s 50 day moving average price is $2.63 and its 200-day moving average price is $2.98.

AC Immune (NASDAQ:ACIU) last released its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. Sell-side analysts predict that AC Immune will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On AC Immune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACIU. Squarepoint Ops LLC bought a new position in AC Immune in the 4th quarter worth about $118,000. Two Sigma Advisers LP bought a new position in AC Immune in the fourth quarter worth approximately $36,000. Cantor Fitzgerald L. P. bought a new position in AC Immune in the fourth quarter worth approximately $68,000. Jane Street Group LLC purchased a new position in AC Immune during the 4th quarter worth $66,000. Finally, Northern Trust Corp bought a new stake in AC Immune during the 4th quarter valued at $1,088,000. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.